<DOC>
	<DOC>NCT02730377</DOC>
	<brief_summary>This trial is conducted globally. The aim of the trial is to investigate efficacy in controlling glycaemia with Victoza® (liraglutide) as add-on to metformin background treatment vs. OADs as add-on to metformin background treatment for 104 weeks of treatment in subjects with type 2 diabetes.</brief_summary>
	<brief_title>Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Meglitinide</mesh_term>
	<mesh_term>2,4-thiazolidinedione</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<mesh_term>Glycoside Hydrolase Inhibitors</mesh_term>
	<mesh_term>Dipeptidyl-Peptidase IV Inhibitors</mesh_term>
	<criteria>Male or female at least 18 years of age at the time of signing informed consent Subjects diagnosed (clinically) with type 2 diabetes equal to or above 90 days prior to the screening visit Stable daily dose of metformin as monotherapy equal to or above 1500 mg or maximum tolerated dose within 60 days prior to the screening visit HbA1c 7.59.0% (5975 mmol/mol) (both inclusive) and measured within the last 90 days prior to the screening visit Female who is pregnant, breastfeeding or intends to become pregnant or is of childbearing potential and not using adequate contraceptive methods (adequate contraceptive measures as required by local regulation or practice) Treatment with any medication for the indication of diabetes other than metformin in a period of 60 days before the screening visit. An exception is shortterm treatment (below or equal to 7 days in total) with insulin in connection with intercurrent illness Receipt of any investigational medicinal product within 30 days before the screening visit Any disorder, which in the investigator's opinion might jeopardise subject's safety or compliance with the protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>